Drug regulation and drug information--who should do what to whom?

Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.

Clinical pharmacology and therapeutics·2015

Clinical and regulatory features of drugs not initially approved by the FDA.

Clinical pharmacology and therapeutics·2013

Defining "innovativeness" in drug development: a systematic review.

Clinical pharmacology and therapeutics·2013

Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2012

Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.

BMJ (Clinical research ed.)·2012